Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market
November 29, 2022 07:30 ET
|
Avicanna Inc.
Developed through Avicanna’s scientific platform, the patent-pending technology provides infusion of a range of cannabinoids into various beverages Initial commercial use of the technology is a THC...
Avicanna Reports Q3 2022 Financial Statement
November 14, 2022 07:30 ET
|
Avicanna Inc.
TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY...
Avicanna Announces Closing of Non-Brokered Private Placement
November 11, 2022 07:30 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Announces Extension of Term Loan
October 31, 2022 17:00 ET
|
Avicanna Inc.
TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy
October 20, 2022 07:30 ET
|
Avicanna Inc.
TORONTO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Introduces a New Medical Cannabis Education Online Portal, “Avicenna Academy” for Health Care Professionals
October 18, 2022 07:30 ET
|
Avicanna Inc.
The education portal provides modules, case studies and other resources related to medical cannabis for Health Care Professionals Established with the support of experts in the fields of pain...
Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto
September 15, 2022 09:09 ET
|
Avicanna Inc.
Dr. Mac Burnham’s team will explore Avicanna’s drug candidate and its proprietary combination of cannabinoids in pre-clinical model for seizures. Avicanna further expands its current research and...
Avicanna Announces Results of Annual General and Special Meeting
September 01, 2022 07:30 ET
|
Avicanna Inc.
TORONTO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Announces Closing of Strategic Private Placement
August 17, 2022 17:00 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Reports Q2 2022 Financial Statement
August 15, 2022 17:00 ET
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...